Cancer wars: natural products strike back

被引：97

作者：

Basmadjian, Christine ^{[1
,2
]}

Zhao, Qian ^{[1
,2
]}

Bentouhami, Embarek ^{[3
]}

Djehal, Amel ^{[1
,3
]}

Nebigil, Canan G. ^{[4
]}

Johnson, Roger A. ^{[5
]}

Serova, Maria ^{[2
]}

de Gramont, Armand ^{[2
]}

Faivre, Sandrine ^{[2
,6
]}

Raymond, Eric ^{[2
,6
]}

Desaubry, Laurent G. ^{[1
]}

机构：

[1] Univ Strasbourg, CNRS, UMR7200, Therapeut Innovat Lab, Illkirch Graffenstaden, France

[2] AAREC Filia Res, Clichy, France

[3] Univ Ferhat Abbas, Fac Technol, Dept Proc Engn, LCIMN Lab, Setif, Algeria

[4] Univ Strasbourg, CNRS, Biotechnol & Cell Signaling Lab, Illkirch Graffenstaden, France

[5] SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA

[6] Beaujon Univ Hosp, AP HP, INSERM, U728,Dept Med Oncol, Clichy, France

来源：

FRONTIERS IN CHEMISTRY | 2014年 / 2卷

关键词：

natural products; cancer; drug discovery; pharmacognosy; molecular targets; privileged structures; PROTEIN-KINASE-C; HUMAN CYTOCHROME P450(17-ALPHA); ECTEINASCIDIN; 743; PHASE-I; CRYSTAL-STRUCTURE; VINFLUNINE; 20'; 20'-DIFLUORO-3'; 4'-DIHYDROVINORELBINE; ANTIPROLIFERATIVE ACTIVITY; RAPAMYCIN AY-22,989; ANTITUMOR-ACTIVITY; SYNTHETIC BIOLOGY;

D O I：

10.3389/fchem.2014.00020

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Natural products have historically been a mainstay source of anticancer drugs, but in the 90's they fell out of favor in pharmaceutical companies with the emergence of targeted therapies, which rely on antibodies or small synthetic molecules identified by high throughput screening. Although targeted therapies greatly improved the treatment of a few cancers, the benefit has remained disappointing for many solid tumors, which revitalized the interest in natural products. With the approval of rapamycin in 2007, 12 novel natural product derivatives have been brought to market. The present review describes the discovery and development of these new anticancer drugs and highlights the peculiarities of natural product and new trends in this exciting field of drug discovery.

引用

页数：18

共 148 条

[1] TOTAL SYNTHESIS OF HALICHONDRIN-B AND NORHALICHONDRIN-B [J].

AICHER, TD ;

BUSZEK, KR ;

FANG, FG ;

FORSYTH, CJ ;

JUNG, SH ;

KISHI, Y ;

MATELICH, MC ;

SCOLA, PM ;

SPERO, DM ;

YOON, SK .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1992, 114 (08) :3162-3164

[2]

[Anonymous], 1976, Chin Med J (Engl), V2, P263

[3]

[Anonymous], 1994, ANN ONCOL

[4] Ready for a comeback of natural products in oncology [J].

Bailly, Christian .

BIOCHEMICAL PHARMACOLOGY, 2009, 77 (09) :1447-1457

[5]

Balog A., 1996, ANGEW CHEM-GER EDIT, V108, P2976

[6] Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A [J].

Basmadjian, Christine ;

Thuaud, Frederic ;

Ribeiro, Nigel ;

Desaubry, Laurent .

FUTURE MEDICINAL CHEMISTRY, 2013, 5 (18) :2185-2197

[7] Trading on traditional medicines [J].

Basu, P .

NATURE BIOTECHNOLOGY, 2004, 22 (03) :263-265

[8] Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells [J].

Benhadji, K. A. ;

Serova, M. ;

Ghoul, A. ;

Cvitkovic, E. ;

Le Tourneau, C. ;

Ogbourne, S. M. ;

Lokiec, F. ;

Calvo, F. ;

Hammel, P. ;

Faivre, S. ;

Raymond, E. .

BRITISH JOURNAL OF CANCER, 2008, 99 (11) :1808-1815

[9] Vinflunine: a novel antitubulin agent in solid malignancies [J].

Bennouna, J ;

Campone, M ;

Delord, JP ;

Pinel, MC .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (10) :1259-1267

[10] Phase I and pharmacokientic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours [J].

Bennouna, J ;

Fumoleau, P ;

Armand, JP ;

Raymond, E ;

Campone, M ;

Delgado, FM ;

Puozzo, C ;

Marty, A .

ANNALS OF ONCOLOGY, 2003, 14 (04) :630-637

← 1 2 3 4 5 6 7 8 9 10 →